Editor's Note: The world is reeling from the COVID-19 crisis and the vulnerable segments of our society are the most at risk. Microsoft News India is supporting HelpAge India buy hygiene kits for the elderly. You can help the charity reach many more. Donate here for the cause (you will be directed to the HelpAge India site).

Remdesivir, a drug thought to be one of the best prospects for treating Covid-19, failed to have any effect in the first full trial, it has been revealed.



The drug is in short supply globally because of the excitement it has generated. It is one of the drugs Donald Trump claimed was “promising”.

Also watch: There is nothing hidden from the US, says WHO (Video by Reuters)

In a “gold standard” trial of 237 patients, some of whom received remdesivir while others did not, the drug did not work. The trial was also stopped early because of side-effects.



News of the failure was posted on a World Health Organization clinical trials database, but later removed. A WHO spokesman said it had been put up too soon, by accident.

“A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments,” said Tarik Jasarevic, a WHO spokesperson.

© Photograph: Reuters The antiviral medication remdesivir. The WHO said a document on the drug’s efficacy in treating the novel coronavirus still awaited peer review.

The drug, made by the US company Gilead Sciences, is an antiviral that was trialled in Ebola, but which failed to show benefits in Africa.



In the race for drugs that might work against Covid-19, many doctors have given remdesivir to patients on “compassionate grounds” without waiting for trials. Because of the interest in it the world’s biggest trial of possible treatments for Covid-19 at Oxford has not been able to include it, because researchers could not obtain supplies.

The trial of the drug in China, with patients with severe Covid-19 disease, may cause some doctors pause. Gilead, however, claimed there were still signs that it could be useful, possibly in patients with milder disease.

In the trial 158 patients were randomly assigned to be given remdesivir, while 79 others had standard care with a placebo instead. There was no difference in the groups as to how quickly patients recovered. Just under 14% of those on remdesivir died, compared with nearly 13% of those not taking the treatment.

In pics: Coronavirus (COVID-19) outbreak around the world

“In this study of hospitalised adult patients with severe Covid-19, [which] was terminated prematurely, remdesivir was not associated with clinical or virological benefits,” said the report on the WHO website.



The report added: “Remdesivir was stopped early in 18 (11.6%) patients because of adverse effects, compared to 4 (5.1%) in the control group.” There were no details in the short report of the side effects which caused the trial to be halted.

Just a week ago it emerged that researchers in Chicago were excited by the results of a Gilead-run trial of remdesivir in 125 patients. Nearly all of those people were discharged within a week, according to STAT News, which follows the pharmaceutical industry. However, there was no placebo group, which means researchers cannot be sure that the drug made the difference and not something else.

Remdesivir is one of a handful of drugs that have been enthusiastically backed by doctors and politicians as potential cures for Covid-19. There has also been a rush to give patients hydroxychloroquine, a less-toxic version of the antimalarial chloroquine. That has led to shortages for people who need to take it for lupus, a disease affecting the immune system.

Scientists who want to see proper trials conducted are likely to point to the remdesivir trial failure as strong evidence of the dangers of giving out even tested drugs on compassionate grounds for a disease that is so novel.

Follow the government's latest travel advice if you are planning a trip outside India or travelling back to India from affected areas. You can also read World Health Organization's advice on basic protective measures against the virus. WHO has also busted some myths surrounding coronavirus. The Ministry of Health's special helpline is available at +91-11-23978046 and ncov2019@gmail.com.